Defiance Autism Impact ETF
Defiance Autism Impact ETF reported 38 holdings worth US$1.35M as of Jun 30, 2026 (Form N-PORT)
As of Jun 30, 2026 · Filed Aug 28, 2026
Defiance Autism Impact ETF reported 38 holdings worth US$1.35M as of Jun 30, 2026. Largest: Definium Therapeutics, Inc., Neuren Pharmaceuticals Limited and Lifestance Health Group, Inc. Filed Aug 28, 2026 (Form N-PORT).
- Holdings
- 38
- Value as reported
- US$1.35M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Definium Therapeutics, Inc. | 1,370 | US$64,445 | 4.8% |
| Neuren Pharmaceuticals Limited | 3,554 | US$43,704 | 3.2% |
| Lifestance Health Group, Inc. | 3,838 | US$41,105 | 3.0% |
| Otsuka Holdings Co., Ltd. | 600 | US$39,889 | 3.0% |
| Acadia Healthcare Company, Inc. | 1,328 | US$39,216 | 2.9% |
| Acadia Pharmaceuticals Inc. | 1,544 | US$39,063 | 2.9% |
| Maplight Therapeutics, Inc. | 1,088 | US$38,994 | 2.9% |
| Abbvie Inc. | 146 | US$36,739 | 2.7% |
| Brightspring Health Services, Inc. | 524 | US$36,544 | 2.7% |
| Revvity, Inc. | 326 | US$36,271 | 2.7% |
| Bright Horizons Family Solutions Inc. | 506 | US$35,865 | 2.7% |
| Medicover Ab Class B | 1,496 | US$35,552 | 2.6% |
| Ipsen Sa | 182 | US$35,124 | 2.6% |
| Sumitomo Pharma Co.ltd. | 3,800 | US$35,095 | 2.6% |
| Johnson & Johnson | 138 | US$35,048 | 2.6% |
| Brainsway Ltd | 2,250 | US$34,898 | 2.6% |
| Pearson Plc | 2,182 | US$34,637 | 2.6% |
| Anavex Life Sciences Corp. | 13,216 | US$34,229 | 2.5% |
| Novartis Ag | 218 | US$34,209 | 2.5% |
| Life Healthcare Group Holdings Limited | 53,486 | US$34,037 | 2.5% |
| Biomarin Pharmaceutical Inc. | 594 | US$33,989 | 2.5% |
| Kpj Healthcare Bhd. | 42,600 | US$33,955 | 2.5% |
| Repligen Corporation | 248 | US$33,837 | 2.5% |
| Roche Holding Ltd | 82 | US$33,831 | 2.5% |
| Supernus Pharmaceuticals, Inc. | 726 | US$33,766 | 2.5% |
| Jazz Pharmaceuticals Plc | 140 | US$33,736 | 2.5% |
| Eli Lilly And Company | 28 | US$33,584 | 2.5% |
| Bristol-myers Squibb Company | 580 | US$33,420 | 2.5% |
| Gsk Plc | 1,264 | US$33,234 | 2.5% |
| Vanda Pharmaceuticals Inc. | 5,416 | US$33,146 | 2.5% |
| Graham Holdings Company | 28 | US$31,960 | 2.4% |
| Teva Pharmaceutical Industries Limited | 1,008 | US$31,762 | 2.4% |
| Takeda Pharmaceutical Co. Ltd. | 1,000 | US$31,718 | 2.3% |
| Grand Canyon Education, Inc. | 218 | US$31,198 | 2.3% |
| H. Lundbeck A/s Class A | 4,768 | US$30,980 | 2.3% |
| Shionogi & Co., Ltd. | 1,800 | US$30,889 | 2.3% |
| Pfizer, Inc. | 1,262 | US$30,389 | 2.2% |
| Stride, Inc. | 332 | US$28,632 | 2.1% |
Source
View original at SEC
Related